Literature DB >> 16554968

A genetic strategy to overcome the senescence of primary meningioma cell cultures.

Gilson S Baia1, Alison L Slocum, Jeanette D Hyer, Anjan Misra, Nouzhan Sehati, Scott R VandenBerg, Burt G Feuerstein, Dennis F Deen, Michael W McDermott, Anita Lal.   

Abstract

Even though meningiomas are the second most common brain tumor in adults, little is known about the molecular basis of their growth and development. The lack of suitable cell culture model systems is an impediment to this understanding. Most studies on meningiomas rely on primary, early passage cell lines that eventually senesce or a few established cell lines that have been derived from aggressive variants of meningiomas. We have isolated three primary meningioma cell lines that are negative for telomerase activity. We can overcome the senescence of a Grade III derived meningioma cell line by expressing the telomerase catalytic subunit (hTERT), whereas Grade I meningioma cell lines require the expression of the human papillomavirus E6 and E7 oncogenes in conjunction with hTERT. Meningioma cell lines, immortalized in this manner, maintain their pre-transfection morphology and form colonies in vitro. We have confirmed the meningothelial origin of these cell lines by assessing expression of vimentin and desmoplakin, characteristic markers for meningiomas. Additionally, we have karyotyped these cell lines using array CGH and shown that they represent a spectrum of the genetic diversity seen in primary meningiomas. Thus, these cell lines represent novel cellular reagents for investigating the molecular oncogenesis of meningiomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554968     DOI: 10.1007/s11060-005-9076-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

Review 1.  Cellular senescence as a tumor-suppressor mechanism.

Authors:  J Campisi
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

2.  Meningioma transcript profiles reveal deregulated Notch signaling pathway.

Authors:  Ileana C Cuevas; Alison L Slocum; Peter Jun; Joseph F Costello; Andrew W Bollen; Gregory J Riggins; Michael W McDermott; Anita Lal
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

3.  Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.

Authors:  K Ikeda; Y Saeki; C Gonzalez-Agosti; V Ramesh; E A Chiocca
Journal:  J Neurosurg       Date:  1999-07       Impact factor: 5.115

4.  Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas.

Authors:  G Hodgson; J H Hager; S Volik; S Hariono; M Wernick; D Moore; N Nowak; D G Albertson; D Pinkel; C Collins; D Hanahan; J W Gray
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

5.  Induction of apoptosis in primary meningioma cultures by fenretinide.

Authors:  Vinay K Puduvalli; Jessica T Li; Ling Chen; Ian E McCutcheon
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

Review 6.  Regulation of the human telomerase reverse transcriptase gene.

Authors:  Anne-Lyse Ducrest; Henrietta Szutorisz; Joachim Lingner; Markus Nabholz
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

Review 7.  Vimentin: the conundrum of the intermediate filament gene family.

Authors:  R M Evans
Journal:  Bioessays       Date:  1998-01       Impact factor: 4.345

Review 8.  Aspects of the structure and assembly of desmosomes.

Authors:  I D Burdett
Journal:  Micron       Date:  1998-08       Impact factor: 2.251

9.  Gene therapy for meningioma: improved gene delivery with targeted adenoviruses.

Authors:  Clemens M F Dirven; Jacques Grill; Martine L M Lamfers; Paul Van der Valk; Angelique M Leonhart; Victor W Van Beusechem; Hidde J Haisma; Herbert M Pinedo; David T Curiel; W Peter Vandertop; Winald R Gerritsen
Journal:  J Neurosurg       Date:  2002-08       Impact factor: 5.115

10.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.

Authors:  T Kiyono; S A Foster; J I Koop; J K McDougall; D A Galloway; A J Klingelhutz
Journal:  Nature       Date:  1998-11-05       Impact factor: 49.962

View more
  17 in total

1.  Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells.

Authors:  Venkateswara Rao Gogineni; Arun Kumar Nalla; Reshu Gupta; Dzung H Dinh; Jeffrey D Klopfenstein; Jasti S Rao
Journal:  Cancer Lett       Date:  2011-09-06       Impact factor: 8.679

2.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

3.  Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.

Authors:  Okay Saydam; Ozlem Senol; Tieneke B M Schaaij-Visser; Thang V Pham; Sander R Piersma; Anat O Stemmer-Rachamimov; Thomas Wurdinger; Saskia M Peerdeman; Connie R Jimenez
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

4.  Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.

Authors:  Christine G Skibinski; Tara Williamson; Gregory J Riggins
Journal:  J Neurooncol       Date:  2018-11-09       Impact factor: 4.130

Review 5.  Meningioma mouse models.

Authors:  Michel Kalamarides; Matthieu Peyre; Marco Giovannini
Journal:  J Neurooncol       Date:  2010-08-24       Impact factor: 4.130

Review 6.  Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options.

Authors:  Chaoying Qin; Meng Huang; Yimin Pan; Yuzhe Li; Wenyong Long; Qing Liu
Journal:  Brain Tumor Pathol       Date:  2021-04-26       Impact factor: 3.298

7.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Authors:  Katherine Striedinger; Scott R VandenBerg; Gilson S Baia; Michael W McDermott; David H Gutmann; Anita Lal
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

9.  N-ethyl-N-nitrosourea (ENU)-induced meningiomatosis and meningioma in p16(INK4a)/p19(ARF) tumor suppressor gene-deficient mice.

Authors:  James P Morrison; Hiroshi Satoh; Julie Foley; John L Horton; June K Dunnick; Grace E Kissling; David E Malarkey
Journal:  Toxicol Pathol       Date:  2007-10       Impact factor: 1.902

10.  Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas.

Authors:  Gilson S Baia; Stefano Stifani; Edna T Kimura; Michael W McDermott; Russell O Pieper; Anita Lal
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.